Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the TULP1 gene.
Features include always present findings: Undetectable electroretinogram, Nyctalopia, Nystagmus, and Reduced visual acuity and others. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Nystagmus, Retinal arteriolar constriction, Posterior subcapsular cataract |
TULP1 function has not been fully characterized.
Retinitis pigmentosa 14 is associated with mutations in the TULP1 gene on chromosome 6.
Genetic testing for TULP1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 14 has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for retinitis pigmentosa 14.
179 publications have been identified in PubMed for retinitis pigmentosa 14. Research spans Basic Science / Preclinical (30%), Epidemiology / Natural History (26%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 53 | 30% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:46 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Age of onset: infancy.
47 |
26% |
Research summaries | 30 | 17% |
Patient case studies | 19 | 11% |
Testing and diagnosis research | 11 | 6% |
New treatment approaches | 9 | 5% |
Clinical study results | 8 | 4% |
Other research | 2 | 1% |
Shan T (2026). [PMID: 42194986](https://pubmed.ncbi.nlm.nih.gov/42194986/). *Genes (Basel)*. [Basic Science / Preclinical]
Chen Y (2026). [PMID: 41732728](https://pubmed.ncbi.nlm.nih.gov/41732728/). *PeerJ*. [Basic Science / Preclinical]
Tang W (2026). [PMID: 41729366](https://pubmed.ncbi.nlm.nih.gov/41729366/). *Int Ophthalmol*. [Basic Science / Preclinical]
Aghajani J (2026). [PMID: 41217041](https://pubmed.ncbi.nlm.nih.gov/41217041/). *J Investig Med*. [Basic Science / Preclinical]
Huchzermeyer C (2026). [PMID: 41718256](https://pubmed.ncbi.nlm.nih.gov/41718256/). *Vision (Basel)*. [Basic Science / Preclinical]
Cao LY (2026). [PMID: 41912321](https://pubmed.ncbi.nlm.nih.gov/41912321/). *Ophthalmic Genet*. [Epidemiology / Natural History]
Ren CY (2026). [PMID: 42157903](https://pubmed.ncbi.nlm.nih.gov/42157903/). *PeerJ*. [Basic Science / Preclinical]
Asadollahzadeh E (2026). [PMID: 41767075](https://pubmed.ncbi.nlm.nih.gov/41767075/). *Clin Case Rep*. [Case Report / Case Series]
Alenazi M (2026). [PMID: 41980014](https://pubmed.ncbi.nlm.nih.gov/41980014/). *Am J Case Rep*. [Case Report / Case Series]
Liu Y (2026). [PMID: 41448483](https://pubmed.ncbi.nlm.nih.gov/41448483/). *Am J Ophthalmol*. [Epidemiology / Natural History]